Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 5, 2007, Pages 643-650

  Lima, Marcos Venício Alves ^a   Ferreira, Francisco Valdeci ^a   Macedo, Francisco Yuri Bulcão ^b   De Castro Brito, Gerly Anne ^b   Ribeiro, Ronaldo Albuquerque ^a,b  

^a Instituto do Cancer do Ceara   (Brazil)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Hemorrhagic cystitis; Histopathology; Ifosfamide; Mesna

Indexed keywords

IFOSFAMIDE; MESNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER MUCOSA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DRUG MEGADOSE; EDEMA; EROSION; FEMALE; HEMORRHAGIC CYSTITIS; HISTOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYSTOSCOPY; EDEMA; ERYTHROCYTES; ETOPOSIDE; EXOCYTOSIS; FEMALE; HEMORRHAGE; HUMANS; IFOSFAMIDE; MALE; MESNA; MIDDLE AGED; URINARY BLADDER; URINARY BLADDER DISEASES; UROTHELIUM;

EID: 33847142805     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0307-5     Document Type: Article

References (22)

1. Brade WP, Herdrich K, Varini M (1985) Ifosfamide - pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1
2. Brock N, Pohl J (1983) The development of mesna for regional detoxification. Cancer Treat Rev 10:33-43
3. Burket H (1983) Clinical overview of mesna. Cancer Treat Rev 10(Suppl A):175-181
4. Cox PJ (1979) Cyclophosphamide cystitis - identification of acrolein as the causative agent. Biochem Pharmacol 28:2045-2049
5. Dechant KL, Brogden RN, Pilkington T, Faulds D (1991) Ifosfamide/Mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42:428-467
6. Etlik O, Tomur A, Deveci S, Piskin I, Pekcan M (1997) Comparison of uroprotective efficacy of Mesna and HBO treatments in cyclophosphamide-induced hemorrhagic cystitis. J Urol 158:2296-2299
7. Foad BSI, Hess EV (1976) Urinary bladder complications with cyclophosphamide therapy. Arch Intern Med 136:616-619
8. Gomes TNA, Santos CC, Souza-Filho MVP, Cunha FQ, Ribeiro RA (1995) Participation of TNF-α and IL-1 in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Braz J Med Biol Res 28:1103-1108
9. Hensley ML, Schuchter ML, Lindley C, Meropol NJ et al (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17:3333-3355
10. Higgs D, Nagy C, Einhorn LH (1989) Ifosfamide: a clinical review. Semin Oncol Nurs 5:70-77
11. Hu VY, Malley S, Dattilio A, Folsom SB, Zvara P, Vizzard MA (2003) COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat. Am J Physiol Regul Integr Comp Physiol 284:574-585
12. Gray KJ, Engelmann UH, Johnson EH, Fishman IJ (1986) Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. J Urol 133:497-500
13. Katz A, Epelman S, Anelli A et al (1995) A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 121:128-131
14. Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G et al (2003) Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin Cancer Res 9:5829-5834
15. Morais MM, Belarmino-Filho JN, Brito GAC, Ribeiro RA (1999) Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna. Braz J Med Biol Res 32:1211-1215
16. Pyeritz R, Droller MJ, Bender WL, Saral R (1978) An approach to control of massive hemorrhage in cyclophosphamide-induced cystitis by intravenous vasopressin: a case report. J Urol 120:253-254
17. Ratliff TR, Willians RD (1998) Hemorrhagic cystitis, chemotherapy, and bladder toxicity. J Urol 159:1044
18. Ribeiro RA, Freitas HC, Campos MC et al (2002) Tumor necrosis factor-α and interleukin-1β mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. J Urol 150:2229-2234
19. Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL (1991) Mesna versus hyperhydration for the prevention of cyclophosphamide- induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 11:2016-2020
20. Souza-Filho MVP, Lima MVA, Pompeu MML, Ballejo G, Cunha FQ, Ribeiro RA (1997) Involvement of nitric oxide in the pathogenesis of cyclophosphamide- induced hemorrhagic cystitis. Am J Pathol 150:247-256
21. Theman H, Oberdorf E, Brock N, Pohl J (1987) Electron microscopic investigations of cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna. Urol Int 42:37-43
22. Vieira MM, Brito GA, Belarmino-Filho JN, Macedo FY, Nery EA, Cunha FQ, Ribeiro RA (2003) Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. Int J Urol 10(11):595-602